Tracking a pancreatic cancer device in real-world patient care

OSPREY is a global tracking study that follows patients who receive OncoSil™, a radioactive device implanted directly into pancreatic tumors to help treat advanced pancreatic cancer. Researchers want to understand how well the device works and how safe it is when used in real hospitals and cancer centers around the world.

Now that this treatment is available in hospitals, doctors and the manufacturer want to gather long-term information from actual patients to make sure the device is performing as expected and to identify any safety concerns that might not have shown up in smaller trials.